(RTTNews) - While reporting financial results for the third quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) provided its adjusted earnings and sales growth guidance for the fourth quarter, and trimmed its full-year 2026 outlook.
Publicznie pokazujemy glowna mysl. Utworz darmowe konto, aby czytac caly artykul, zapisac go, omowic i polaczyc z kontekstem rynkowym oraz OSINT.